Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Pozi P2 HER2 positive metastatic breast cancer study. So will they release data at SABCS Dec 4 - 8? From the 1st Q CC

Edward Patrick White, H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst [12]
------------------------------------------------------------------------
So just a couple of things. First of all, if you can make a comment on your pozi Phase II HER2 positive metastatic breast cancer study. Just how that's progressing? And when we can see data from there?
------------------------------------------------------------------------
Joseph W. Turgeon, Spectrum Pharmaceuticals, Inc. - President, CEO & Director [13]
------------------------------------------------------------------------
Okay. Well, first -- let me let Zane Yang answer that. He's the Director of Development here.
------------------------------------------------------------------------
Zane Yang, Spectrum Pharmaceuticals, Inc. - SVP of Clinical Development [14]
------------------------------------------------------------------------
Thank you for the questions. This is Zane. Also, I'm the leader for the clinical development. And just update for your interest of pozi in HER2 positive for breast cancer. And as you know, this is a single agent -- single arm therapy in pretreated advanced metastatic breast cancer patient. And in the recent Global Breast Cancer Conference in Korea, we reported the first cohort study result demonstrate the clinical efficacy and the safety profile. In that poster publicly available at this time, we demonstrated in the first cohort of 33 patient, we have more than 21% of confirmed response rate, which is in line of this preheavily treated patient population receive available -- currently available therapy and the safety profile is also within -- around the safety profile in the class of chart.
------------------------------------------------------------------------
Joseph W. Turgeon, Spectrum Pharmaceuticals, Inc. - President, CEO & Director [15]
------------------------------------------------------------------------
And I'll add this, I think, to get one of the gist to your questions. I think the study is enrolling very well.
------------------------------------------------------------------------
Edward Patrick White, H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst [16]
------------------------------------------------------------------------
Okay. When do you expect to see full enrollment or have you mentioned that?
------------------------------------------------------------------------
Joseph W. Turgeon, Spectrum Pharmaceuticals, Inc. - President, CEO & Director [17]
------------------------------------------------------------------------
Yes. We usually don't comment on that. But it is enrolling well, that I can tell you.

The study protocol does state that the Estimated Primary Completion Date is December 2018. Maybe they'll let us know at the CC next week.